Treatment strategies for hypertension in patients with type 1 diabetes. (2nd July 2020)

• Record Type: Journal Article
• Authors: Katsimardou, Alexandra; Imprialos, Konstantinos; Stavropoulos, Konstantinos; Sachinidis, Alexandros; Doumas, Michalis; Athyros, Vasilios G.
• Is Part Of: Expert opinion on pharmacotherapy. Volume 21:Number 10(2020)
• Page Start: 1241
• Page End: 1252
• Publication Date: 2020-07-02
• Subjects: Angiotensin-converting enzyme inhibitors -- angiotensin receptor blockers -- hypertension -- renin-angiotensin-aldosterone system inhibitors -- SGLT2 inhibitors -- type 1 diabetes; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2020.1729124
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. Areas covered: The purpose of this review is to present the current definitions, epidemiological data and prevalence rates of hypertension in T1DM, as well as to describe current therapeutic options. Expert opinion: Hypertension affects around a third of the type 1 diabetic population, with higher prevalence rates in older individuals with longer disease duration. Although hypertension affects a substantial proportion of T1DM individuals, blood pressure control rates are disappointingly low. Alongside lifestyle modification, antihypertensive treatment should be initiated in those with blood pressure above 140/90 mmHg, with a systolic blood pressure target of 130 mmHg and lower, if tolerated. In those with established CVD or diabetic nephropathy, systolic blood pressure targets below 130 mmHg should be pursued. Initial pharmacotherapy should consist of a renin-angiotensin-aldosterone system inhibitor. There is an urgent need for good quality data regarding proper antihypertensive treatment initiation, optimal BP targets and optimal antihypertensive treatment for better clinical outcomes.